global
outbreak
sever
acut
respiratori
syndrom
sar
start
march
caus
sarsassoci
coronaviru
sarscov
cumul
number
case
countri
region
juli
total
number
death
ratio
owe
lack
knowledg
new
seriou
diseas
differ
treatment
modal
use
empir
much
uncertainti
overwhelm
situat
larg
number
ill
patient
deterior
rapidli
prevent
anxiou
physician
perform
random
control
treatment
trial
regard
danger
uneth
face
lifethreaten
condit
mani
treatment
option
includ
antivir
agent
immunosuppress
agent
convalesc
plasma
immunoglobulin
noninvas
posit
pressur
ventil
nippv
tradit
chines
medicin
tcm
introduc
basi
differ
rational
first
sar
initi
viral
replic
phase
peak
around
day
respons
viral
load
take
form
inflammatori
cell
infiltr
tissu
overproduct
cytokin
result
immunopatholog
damag
thu
therapeut
window
exploit
prevent
diseas
progress
potent
antivir
agent
avail
ribavirin
chosen
use
due
wide
spectrum
activ
despit
rather
weak
sarscov
proteas
inhibitor
studi
experiment
evid
inhibit
proteas
essenti
life
cycl
sarscov
second
corticosteroid
util
mitig
tissuedamag
effect
inflammatori
cell
cytokin
treat
acut
respiratori
distress
syndrom
ard
bronchiol
obliteran
organ
pneumonia
boop
septic
shock
may
occur
third
convalesc
plasma
administ
belief
larg
amount
neutral
antibodi
present
block
action
sarscov
fourth
immunoglobulin
employ
salvag
therapi
patient
inexor
deterior
despit
usual
treatment
approach
base
immunomodulatori
effect
immunoglobulin
includ
competit
occup
macrophag
receptor
neutral
activ
complement
cytokin
superantigen
inhibit
activ
lymphocyt
fifth
applic
nippv
sar
origin
use
manag
patient
chronic
obstruct
airway
diseas
complic
sever
communityacquir
pneumonia
sixth
tcm
use
china
known
efficaci
treatment
fever
throughout
age
absenc
consensu
optim
therapeut
strategi
variou
approach
devis
elsewher
world
antivir
therapi
adopt
start
hong
kong
outbreak
sar
consid
viral
infect
even
identif
sarscov
detect
sarscov
earli
phase
diseas
found
poor
prognost
sign
one
retrospect
case
analysi
patient
posit
rtpcr
test
nasopharyng
aspir
sampl
sarscov
admiss
mean
day
onset
ill
like
advers
outcom
term
surviv
icu
care
assist
ventil
compar
patient
neg
rtpcr
result
prospect
studi
reveal
initi
viral
replic
phase
follow
immunopatholog
phase
end
organdamag
phase
hypothes
viral
antigen
trigger
immun
respons
best
approach
halt
earli
viral
replic
diminish
peak
viral
load
immunopatholog
damag
result
lessen
requir
immunosuppress
may
predispos
patient
nosocomi
infect
particularli
mechan
ventil
ribavirin
chosen
use
empir
due
broad
antivir
spectrum
assumpt
could
provid
coverag
corticosteroid
treatment
wide
util
time
end
patient
hong
kong
receiv
ribavirin
mechan
action
nucleosid
analogu
well
establish
ribavirin
attract
consider
critic
rel
lack
vitro
activ
sarscov
high
concentr
ribavirin
need
inhibit
viru
transient
level
difficult
achiev
clinic
retrospect
uncontrol
cohort
analysi
use
ribavirin
appear
confer
benefit
sar
patient
ribavirin
associ
number
signific
advers
effect
import
one
anemia
one
studi
report
drop
hemoglobin
gdl
patient
anemia
relat
hemolysi
circumst
oxygen
desatur
tissu
hypoxia
exacerb
reduc
oxygen
carriag
capac
low
hemoglobin
import
side
effect
includ
bradycardia
patient
rais
serum
transaminas
patient
teratogen
potenti
ribavirin
given
togeth
corticosteroid
shown
incap
prevent
peak
viral
load
day
onset
ill
thu
ribavirin
controversi
drug
low
efficaci
signific
toxic
urgent
need
find
potent
safer
antivir
agent
quest
effect
agent
sarscov
proteas
inhibitor
lopinavir
combin
ribavirin
found
reach
synergist
inhibitori
concentr
sarscov
laboratori
test
lopinavir
combin
ritonavir
lpvr
licens
treatment
hiv
infect
ritonavir
weak
antivir
agent
increas
serum
level
lopinavir
inhibit
metabol
partner
though
satisfactori
serum
inhibitori
concentr
lopinavir
may
achiev
oral
lpvr
combin
suffici
level
may
reach
intestin
mucosa
sinc
drug
found
excret
unchang
stool
signific
sever
wateri
diarrhea
mark
featur
sar
patient
gastrointestin
mucosa
could
import
reservoir
viral
replic
fecalor
transmiss
open
trial
use
lpvr
combin
togeth
ribavirin
patient
compar
histor
control
shown
patient
lpvr
group
fewer
advers
clinic
outcom
deathacut
respiratori
distress
syndrom
diseas
cours
milder
regard
diarrhea
fever
recurr
worsen
chest
radiograph
addit
lpvr
group
progress
decreas
viral
load
earli
rise
lymphocyt
count
reduct
cumul
dose
puls
methylprednisolon
fewer
episod
nosocomi
infect
anoth
larger
multicent
studi
hong
kong
patient
given
lpvr
combin
initi
therapi
besid
ribavirin
corticosteroid
treatment
associ
reduct
overal
death
rate
intub
rate
compar
match
cohort
receiv
standard
treatment
vs
vs
respect
p
lower
rate
use
methylprednisolon
lower
mean
dose
find
two
studi
suggest
lpvr
combin
ribavirin
may
effect
agent
sar
thought
tissu
damag
respiratori
viral
infect
caus
vigor
system
inflamm
cytokin
storm
induc
earlyrespons
cytokin
tumor
necrosi
factoralpha
interferongamma
exagger
host
cytokin
respons
assum
respons
second
immunopatholog
phase
sar
evid
recent
report
show
mark
elev
cytokin
inflammatori
cytokin
least
week
diseas
onset
also
signific
elev
neutrophil
chemokin
monocyt
chemoattract
chemokin
corticosteroid
significantli
reduc
concentr
day
treatment
find
confirm
activ
cellmedi
immun
hyperinn
inflammatori
respons
sar
accumul
monocytesmacrophag
neutrophil
anoth
rational
favor
steroid
usag
necropsi
evid
infiltr
macrophag
promin
leukocyt
pulmonari
alveoli
hemophagocytosi
lung
accompani
patholog
featur
ard
boop
hemophagocytosi
associ
cytokin
dysregul
cytokin
respons
may
temper
corticosteroid
prevent
fatal
outcom
suggest
ard
etiolog
final
reason
use
corticosteroid
sar
ct
scan
thorax
shown
radiograph
featur
boop
steroidrespons
condit
suggest
immunolog
phenomenon
chest
radiograph
resolut
may
slightli
lag
behind
clinic
recoveri
reason
addit
dose
corticosteroid
despit
taper
corticosteroid
ensu
week
radiolog
opac
usual
continu
improv
use
corticosteroid
may
nevertheless
associ
enhanc
viral
replic
due
suppress
innat
immun
respons
one
studi
document
case
increas
viral
load
follow
puls
methylprednisolon
anoth
studi
also
found
earli
corticosteroid
treatment
day
ill
associ
higher
subsequ
plasma
viral
load
lowdos
corticosteroid
like
prednisolon
mgkgday
usual
use
infect
ard
hand
puls
dose
methylprednisolon
gday
wide
use
sar
especi
patient
deterior
clinic
second
week
whether
puls
corticosteroid
efficaci
unknown
although
number
report
corticosteroid
usag
sar
eman
hong
kong
china
meaning
interpret
retrospect
analys
hamper
methodolog
limit
gener
differ
type
corticosteroid
dose
regimen
time
treatment
initi
cours
diseas
despit
number
studi
publish
systemat
review
metaanalysi
efficaci
corticosteroid
sar
avail
anecdot
case
sar
success
treat
administ
methylprednisolon
puls
correspond
immunosuppress
dose
use
prevent
organ
reject
group
research
studi
respons
patient
sar
variou
steroid
regimen
show
highdos
puls
methylprednisolon
therapi
organ
reject
treatment
rang
efficaci
equal
safe
regimen
lower
dosag
anoth
group
howev
find
use
puls
methylprednisolon
associ
better
outcom
furthermor
one
retrospect
case
seri
found
puls
methylprednisolon
predictor
mortal
multivari
analysi
group
advoc
earli
introduct
highdos
corticosteroid
mostli
puls
methylprednisolon
treatment
sar
other
propos
corticosteroid
use
judici
immunopatholog
phase
sar
toward
end
first
week
begin
second
week
diseas
recommend
dose
lower
puls
methylprednisolon
use
whenev
patient
deterior
clinic
develop
respiratori
distress
latter
approach
seem
gain
accept
use
corticosteroid
sar
especi
high
dose
prolong
period
accompani
signific
side
effect
includ
hyperglycemia
hypokalemia
hypertens
gastrointestin
hemorrhag
particular
nosocomi
infect
occurr
nosocomi
infect
preval
patient
manag
icu
could
manifest
pneumonia
urinari
tract
infect
bacteremia
deepseat
mycosi
easi
distinguish
whether
recurr
fever
later
cours
sar
therapi
particularli
period
corticosteroid
treatment
due
nosocomi
infect
antipseudomon
antibiot
antifung
agent
usual
indic
circumst
patient
appar
clinic
respons
empir
antimicrobi
therapi
opportunist
infect
reason
exclud
higher
puls
methylprednisolon
dose
tri
avascular
necrosi
bone
osteonecrosi
probabl
one
distress
complic
associ
use
corticosteroid
sar
one
recent
studi
patient
magnet
reson
imag
show
evid
subchondr
osteonecrosi
mainli
involv
proxim
femur
patient
addit
nonspecif
subchondr
intramedullari
bone
marrow
abnorm
result
multipl
logist
regress
analysi
confirm
cumul
prednisoloneequival
dose
import
risk
factor
osteonecrosi
joint
pain
common
sar
infect
use
clinic
indic
complic
patient
deterior
irrevoc
despit
receiv
puls
methylprednisolon
convalesc
plasma
obtain
patient
recov
sar
use
last
resort
cell
separ
oper
plasma
exchang
mode
use
harvest
convalesc
plasma
apharesi
experi
kind
treatment
limit
small
retrospect
nonrandom
studi
patient
progress
diseas
ribavirin
puls
methylprednisolon
treatment
plasmatr
group
shorter
hospit
stay
lower
mortal
group
continu
treatment
puls
methylprednisolon
later
studi
group
show
higher
discharg
rate
among
patient
given
plasma
infus
day
ill
anoth
form
salvag
therapi
patient
run
relentless
downhil
cours
intraven
immunoglobulin
ivig
pentaglobin
infus
ivig
nonspecif
hyperimmun
globulin
pentaglobin
igmenrich
immunoglobulin
prepar
retrospect
analysi
patient
sever
sar
demonstr
pentaglobin
safe
probabl
effect
treatment
case
corticosteroid
resist
nevertheless
use
immunoglobulin
associ
risk
venou
thrombosi
noninvas
posit
pressur
ventil
nippv
form
ventilatori
support
tightfit
facemask
nasal
mask
frequent
administ
combin
continu
posit
airway
pressur
bilevel
posit
airway
pressur
patient
impend
respiratori
failur
shown
nippv
reduc
intub
rate
length
icu
stay
mortal
patient
chronic
obstruct
airway
diseas
suffer
sever
communityacquir
pneumonia
sar
clinic
syndrom
often
progress
vari
degre
respiratori
failur
anecdot
report
efficaci
nippv
sar
patient
respiratori
decompens
china
hong
kong
earli
hong
kong
trial
involv
patient
acut
respiratori
failur
secondari
sar
nippv
administ
patient
isol
singl
room
prefer
neg
pressur
adequ
airflow
full
person
protect
equip
exhal
port
gener
roundthetub
airflow
interposit
viralbacteri
filter
mask
exhal
port
retrospect
analysi
show
procedur
start
mean
day
onset
ill
nippv
group
result
avoid
intub
subject
shorter
length
icu
stay
lower
chest
radiographi
score
compar
intub
group
sar
infect
healthcar
worker
care
patient
nippv
later
ban
hong
kong
fear
viral
spread
air
leakag
around
mask
aerosol
gener
howev
evid
show
nippv
use
safe
treatment
option
sar
patient
respiratori
failur
provid
perform
good
precaut
suitabl
set
patient
deterior
fail
improv
day
nippv
nippv
contraind
endotrach
intub
mechan
ventil
consid
ventilatori
approach
similar
caus
ard
plateau
pressur
kept
lower
cm
tendenc
barotrauma
sar
present
therapi
sar
less
satisfactori
much
effort
expend
look
novel
treatment
modal
well
known
viral
infect
stimul
product
interferon
ifn
earli
phase
human
hereditari
immun
respons
cytopath
effect
sarscov
shown
complet
inhibit
vitro
ifn
ifn
ifn
ifn
human
leukocyt
ifn
synergist
inhibit
replic
sarscov
achiev
combin
plu
anim
cell
plu
ribavirin
anim
human
cell
vitro
data
hong
kong
shown
type
interferon
induc
potent
inhibit
sarscov
type
ii
interferon
uncontrol
trial
found
ifn
plu
corticosteroid
improv
oxygen
satur
hasten
radiograph
resolut
lung
opac
lower
level
creatin
kinas
anim
studi
pegyl
associ
significantli
reduc
viral
replic
excret
express
lung
tissu
administ
prophylact
cynomolgu
macaqu
experiment
exposur
sarscov
postexposur
treatment
result
intermedi
outcom
find
provid
basi
pursuit
role
interferon
treatment
prophylaxi
sar
evid
indic
sarscov
enter
human
cell
bind
viral
protein
angiotensinconvert
receptor
though
clinic
signific
find
confirm
recent
studi
highaffin
human
monoclon
antibodi
call
demonstr
strong
neutral
activ
vitro
vivo
protein
hypothes
use
agent
sar
treatment
prophylaxi
howev
note
enhanc
diseas
coronavirus
includ
sarscov
may
occur
antibodi
sever
potenti
treatment
option
may
eventu
prove
valuabl
antisar
agent
investig
activ
compon
liquoric
root
glycyrrhizin
show
signific
viral
inhibit
vitro
sarscov
also
exhibit
vitro
suscept
baicalin
chemic
compound
deriv
herb
scute
huangqin
nelfinavir
found
inhibit
cytopath
effect
induc
sarscov
infect
decreas
product
virion
vero
cell
agent
horizon
intens
research
includ
small
interf
rna
smallmolecul
inhibitor
identifi
chemic
genet
targetdesign
proteinas
inhibitor
exist
drug
use
treatment
hiv
psychot
disord
parasit
infect
tumor
necrosi
factoralpha
inhibitor
nitric
oxid
aminopeptidas
n
inhibitor
sar
outbreak
tradit
chines
medicin
tcm
use
extens
china
larg
experi
accumul
tcm
literatur
compar
western
method
treatment
integr
tcm
western
medicin
treatment
shown
effect
improv
clinic
symptom
shorten
cours
ill
clear
lung
inflamm
prevent
rebound
fever
reduc
durat
corticosteroid
usag
select
case
hong
kong
also
treat
tcm
adjuv
therapi
especi
convalesc
period
benefit
difficult
establish
due
heterogen
type
amount
concoct
constitu
differ
phase
diseas
therapi
start
divers
clinic
condit
patient
variabl
length
treatment
investig
relationship
hazard
death
cure
curedeath
hazard
plot
develop
casefat
rate
hong
kong
singapor
beij
result
show
signific
differ
casefat
rate
beij
area
postul
phenomenon
may
due
differ
treatment
method
possibl
combin
tcm
western
medicin
give
better
result
latter
alon
treatment
sar
aspect
antisar
therapi
certainli
warrant
investig
futur
number
treatment
protocol
report
hong
kong
sar
outbreak
invari
compos
antibiot
combin
dose
rout
administr
ribavirin
stepdown
cours
corticosteroid
week
possibl
puls
methylprednisolon
rescu
case
clinic
worsen
patient
found
one
report
adher
standard
treatment
protocol
result
overal
satisfactori
outcom
treatment
guidelin
intend
use
sar
return
work
consensu
among
expert
hong
kong
end
protocol
format
placebocontrol
doubleblind
random
trial
patient
fulfil
clinic
case
definit
sar
prescrib
broadspectrum
antibiot
cephalosporin
plu
macrolid
penicillin
allerg
antipneumococc
quinolon
penicillinallerg
patient
support
care
upon
laboratori
confirm
sar
accord
definit
patient
condit
stabl
inform
consent
obtain
patient
random
one
two
arm
antivir
arm
placebo
arm
patient
assign
antivir
arm
receiv
ribavirin
lopinavirritonavir
combin
ribavirin
start
g
oral
load
dose
follow
g
oral
total
day
lopinavirritonavir
combin
administ
three
tablet
bid
oral
tablet
contain
lopinavir
mg
ritonavir
mg
total
day
rescu
measur
patient
either
arm
featur
acut
lung
injuri
defin
ratio
kpa
mm
hg
given
either
prednisolon
mgkgday
day
follow
taper
dosag
clinic
improv
everi
day
mgkg
decrement
ii
methylprednisolon
mgkgday
intraven
day
taper
mgkg
everi
day
step
oral
prednisolon
total
week
patient
underli
cardiac
respiratori
condit
initi
nippv
consid
patient
develop
critic
sar
defin
ratio
kpa
mm
hg
progress
deterior
chest
radiograph
nippv
invas
ventil
must
consid
puls
steroid
use
discret
clinician
suggest
regimen
methylprednisolon
mg
per
day
intraven
day
follow
taper
cours
mgkgday
cumul
dose
prefer
exceed
g
similar
consensu
treatment
guidelin
use
ribavirin
corticosteroid
promulg
china
novemb
center
world
like
canada
singapor
liber
use
ribavirin
corticosteroid
hong
kong
interestingli
patient
quit
similar
outcom
usa
support
therapi
alon
use
treat
sar
patient
casefat
rate
howev
direct
comparison
possibl
sinc
probabl
case
none
suspect
case
virolog
evid
sarscov
infect
ribavirin
corticosteroid
cornerston
treatment
sar
outbreak
ribavirin
shown
lack
efficaci
number
studi
use
corticosteroid
report
uncontrol
trial
investig
requir
antiretrovir
formul
lopinavirritonavir
use
ribavirin
found
associ
clinic
benefit
surviv
patient
deterior
despit
puls
methylprednisolon
therapi
may
improv
use
convalesc
plasma
immunoglobulin
like
pentaglobin
nippv
perform
appropri
set
adequ
precaut
prove
effect
patient
develop
respiratori
failur
interferon
novel
agent
activ
investig
may
consider
strengthen
antisar
armamentarium
futur
tcm
yet
untap
wealth
knowledg
becom
import
partner
convent
treatment
strategi
final
optim
treatment
regimen
sar
remain
elus
random
control
treatment
trial
done
especi
intern
collabor
discov
best
form
therapi
